Even though very few studies have so far shown the potential action of PPARγ agonists in the treatment of COVID-19, rosiglitazone can modulate ACE2 expression in animal models (72) and it may also potentially be utilized in diabetic patients with COVID-19 (73). The gene discussed is ACE2; the disease is COVID-19.